NASDAQ: ILMN
Healthcare · Medical - Diagnostics & Research
After hours: $189.45(-0.01%) · as of 6:26 PM ET
Market Cap
$28.67B
52w High
$199.14
52w Low
$88.00
P/E
34.21
Volume
1.74M
Outstanding Shares
151.30M
Price vs Fundamentals
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
The stock rose 72.43% over the last year. Revenue grew 1.25% over the trailing twelve months. Operating margin moved from -11.76% to 20.93%. Free cash flow grew 13.81% over the trailing twelve months.
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 15th percentile of their historical P/FCF range.
Operating margin is at 20.93%. Revenue grew 1.25% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies.
Valuation
Stock splits
Every 1 shares became 2
Profitability & growth
Analyst consensus
26
Buy
18
Hold
6
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Jul 30, 2026
Q3 FY26 · EPS est $1.23 · Revenue est $1.13B
View